Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • PZWL
  • Reduced price
HER2-Positive Breast Cancer

HER2-Positive Breast Cancer

9780323581226
PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 30 DAYS
515.91 zł
438.53 zł Save 77.38 zł Tax included
Lowest price within 30 days before promotion: 438.53 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates todays available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

Product Details
Elsevier
60181
9780323581226
9780323581226

Data sheet

Publication date
2018
Issue number
1
Cover
paperback
Pages count
264
Dimensions (mm)
197 x 240
Weight (g)
660
  • Background/testing

    1. The HER2 alteration in breast cancer

    2. HER2 testing in the era of changing guidelines

    Advanced Disease

    3. Optimal first-line treatment of HER2+ advanced disease

    4. Second line therapy and beyond

    5. HER2+ CNS metastases

    Therapeutics

    6. Neoadjuvant therapy

    7. Adjuvant therapy

    8. Outcomes based on HR status in early stage disease

    9. De-escalation of therapy for small tumor

    Toxicity considerations

    10. Cardiac toxicity of HER2-targeted regimens

    11. Non-cardiac toxicity of HER2-targeted therapy

    Therapies on the horizon

    12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)

    13. Harnessing the immune system in HER2+ disease

    14. Biosimilars

Comments (0)

  • Frequently purchased together

    No products available